| アブストラクト | BACKGROUND: Schizophrenia is a psychiatric disorder characterized by hallucinations, delusions, and other symptoms. Although treatment guidelines for schizophrenia have been established in Japan, drugs are not recommended for pediatric schizophrenia. Additionally, the temporal trends in prescribing antipsychotics for pediatric patients with schizophrenia are unclear. Therefore, we aimed to clarify the trends in antipsychotic prescriptions for Japanese pediatric outpatients from 2015 to 2022. METHODS: Administrative data (as of November 2023) of Japanese pediatric outpatients with schizophrenia aged 0-18 years who visited acute-care diagnosis procedure combination hospitals between January 1, 2015, and December 31, 2022, were included in this study. The target drugs for schizophrenia were all indicated for treating schizophrenia and marketed in Japan as of December 2022. Annual prescription trends for antipsychotics during this period were calculated based on their proportions. The Cochran-Armitage trend test was used to evaluate the proportion of prescriptions for each antipsychotic. RESULTS: The main drugs prescribed for these patients were aripiprazole and risperidone. Among male patients, the proportion of prescriptions for aripiprazole increased significantly from 21.2% in 2015 to 35.9% in 2022, whereas that for risperidone decreased significantly from 47.9% in 2015 to 36.7% in 2022 (both P < 0.001). Among female patients, the proportion of prescriptions for aripiprazole increased significantly from 21.6% in 2015 to 35.6% in 2022, whereas that for risperidone decreased significantly from 38.6% in 2015 to 24.8% in 2022 (both P < 0.001). CONCLUSIONS: Aripiprazole and risperidone were primarily prescribed for pediatric schizophrenia in Japan during the study period. Additionally, the proportion of aripiprazole prescriptions increased over time. |
|---|
| 投稿者 | Kikuchi, Daisuke; Obara, Taku; Obara, Ryo; Hino, Hiroaki; Suzuki, Naoto; Kashiwagura, Shota; Watanabe, Takashi; Ouchi, Ryusuke; Usui, Kensuke; Okada, Kouji |
|---|
| 組織名 | Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital,;1-12-1 Fukumuro, Miyagino-ku, Sendai, 983-8512, Miyagi, Japan.;Division of Molecular Epidemiology, Tohoku University Graduate School of;Medicine, 2-1, Seiryo-machi, Aoba-ku, Sendai, 980-8573, Miyagi, Japan.;Division of Preventive Medicine and Epidemiology, Tohoku University Tohoku;Medical Megabank Organization, 2-1, Seiryo-machi, Aoba-ku, Sendai, 980-8573,;Miyagi, Japan.;Department of Pharmaceutical Sciences, Tohoku University Hospital, 1-1,;Seiryo-machi, Aoba- ku, Sendai, 980-8574, Miyagi, Japan.;Department of Pharmacy, Kawasaki Kokoro Hospital, 72, Kitakawarayama,;Oaza-Kawauchi, Kawasaki-cho, Shibata-gun, Miyagi, 980-8574, Japan.;Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and;Pharmaceutical University, 1-12-1, Fukumuro, Miyagino-ku, Sendai, 980-8512,;kokada@tohoku-mpu.ac.jp.;Miyagi, Japan. kokada@tohoku-mpu.ac.jp. |
|---|
